Rituxan and Avastin do not infringe Sanofi's CMV enhancer patents Lexology (registration) The Court of Appeals for the Federal Circuit recently upheld a summary judgement decision that neither rituximab nor trastuzumab infringes two Sanofi patents (5849522 and 6218140) directed to human cytomegalovirus enhancers. Briefly, enhancers are DNA ... |
